Becker Muscular Dystrophy - Pipeline Insight, 2025

DelveInsight’s, “Becker Muscular Dystrophy – Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Becker Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Becker Muscular Dystrophy Understanding

Becker Muscular Dystrophy: Overview

Becker muscular dystrophy (BMD) is an inherited condition that causes progressive weakness and wasting of the skeletal and cardiac (heart) muscles. It primarily affects males. The age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5 and 15. The symptoms of Becker muscular dystrophy (BMD) may begin anywhere from childhood to a person's early 20s. Muscle weakness often affects the legs and pelvis, and slowly gets worse. Over time, affected people begin to have difficulty walking, frequent falls, difficulty with muscle skills (such as running, hopping, and jumping), and loss of muscle mass. Becker muscular dystrophy (BMD) is caused by specific mutations in the DMD gene. The DMD gene gives the body instructions to make a protein called dystrophin. This protein helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells. Becker muscular dystrophy (BMD) is caused by specific mutations in the DMD gene. The DMD gene gives the body instructions to make a protein called dystrophin. This protein helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells. There is currently no cure for Becker muscular dystrophy (BMD), and management aims to help with symptoms and improve the quality of life.

""Becker Muscular Dystrophy - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Becker Muscular Dystrophy pipeline landscape is provided which includes the disease overview and Becker Muscular Dystrophy treatment guidelines. The assessment part of the report embraces, in depth Becker Muscular Dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Becker Muscular Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Becker Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Becker Muscular Dystrophy.

Becker Muscular Dystrophy Emerging Drugs Chapters

This segment of the Becker Muscular Dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Becker Muscular Dystrophy Emerging Drugs

• Givinostat: Italfarmaco

Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts. The drug is currently being evaluated in Phase II clinical to treat becker muscular dystrophy.

• EDG-5506: Edgewise Therapeutics

Edgewise Therapeutics Continued to advance a Phase I MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD).

Further product details are provided in the report……..

Becker Muscular Dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Becker Muscular Dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Becker Muscular Dystrophy

There are approx. 8+ key companies which are developing the therapies for Becker Muscular Dystrophy. The companies which have their Becker Muscular Dystrophy drug candidates in the most advanced stage, i.e. Phase II include, Italfarmaco.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Becker Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Becker Muscular Dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Becker Muscular Dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Becker Muscular Dystrophy drugs.

Becker Muscular Dystrophy Report Insights

• Becker Muscular Dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Becker Muscular Dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Becker Muscular Dystrophy drugs?
• How many Becker Muscular Dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Becker Muscular Dystrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Becker Muscular Dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Becker Muscular Dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Show more